DataVXACS Applied Materials & InterfacesPaper
journal article·2019-06-05

Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory Syndrome Coronavirus

Xinyu Huang, Meng Li, Yurui Xu, Jikang Zhang, Xia Meng, Xueying An, Lei Sun, Leilei Guo, Xue Shan, Junliang Ge, Jiao Chen, Yadong Luo, Heming Wu, Yu Zhang, Qing Jiang, Xinghai Ning

ACS Applied Materials & Interfaces· Volume 11· Issue 22
Publisher page
Source abstract

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) causes a severe acute respiratory syndrome-like illness with high pathogenicity and mortality due to the lack of effective therapeutics. Currently, only few antiviral agents are available for the treatment of MERS, but their effects have been greatly impaired by low antiviral activity, poor metabolic stability, and serious adverse effects. Therefore, the development of effective treatment for MERS is urgently needed. In this study, a series of heptad repeat 1 (HR1) peptide inhibitors have been developed to inhibit HR1/HR2-mediated membrane fusion between MERS-CoV and host cells, which is the major pathway of MERS-CoV-induced host infections. Particularly, peptide pregnancy-induced hypertension (PIH) exhibits potent inhibitory activity with IC50 of 1.171 μM, and its inhibitory effects can be further increased to 10-fold by forming a gold nanorod complex (PIH-AuNRs). In addition, PIH-AuNRs display enhanced metabolic stability and biocompatibility in vitro and in vivo and, therefore, effectively prevent MERS-CoV-associated membrane fusion. In summary, PIH-AuNRs represent a novel class of antiviral agents and have a great potential in treating MERS in the clinic.
Source: openalex_inverted_index · Quality: baseline

Research context

NanomaterialsBiomaterials

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · COVID-19 Impact on Reproduction · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nanjing National Laboratory of Microstructures, College of Engineering and Applied Sciences, Nanjing University, Nanjing 210093, China

Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing 210029, China

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China

State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China

Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China

Funding

Natural Science Foundation of Jiangsu Province · Fundamental Research Funds for Central Universities Nanjing University · Ministry of Science and Technology of the People's Republic of China · Shuangchuang Program of Jiangsu Province · Thousand Talents Program for Young Researchers · National Natural Science Foundation of China · Scientific Research Foundation of Graduate School of Nanjing University

References (32)

Show source-provided references
1. 10.1128/JVI.01244-1310.1128/JVI.01244-13 ↗
2. 10.1056/NEJMoa130674210.1056/NEJMoa1306742 ↗
3. 10.1056/NEJMc130869810.1056/NEJMc1308698 ↗
4. 10.1056/NEJMoa121172110.1056/NEJMoa1211721 ↗
5. 10.1016/S1473-3099(13)70204-410.1016/S1473-3099(13)70204-4 ↗
6. 10.1128/CMR.00102-1410.1128/CMR.00102-14 ↗
7. 10.1007/s00134-014-3303-y10.1007/s00134-014-3303-y ↗
8. 10.1016/j.ijid.2013.12.00310.1016/j.ijid.2013.12.003 ↗
9. 10.1016/S1473-3099(14)70920-X10.1016/S1473-3099(14)70920-X ↗
10. 10.1093/jac/dkv08510.1093/jac/dkv085 ↗
11. 10.1038/ncomms1509210.1038/ncomms15092 ↗
12. 10.1128/JVI.00128-1310.1128/JVI.00128-13 ↗
13. 10.1038/nature1200510.1038/nature12005 ↗
14. 10.1128/JVI.02433-1310.1128/JVI.02433-13 ↗
15. 10.1021/ja00897a02510.1021/ja00897a025 ↗
16. 10.1128/JVI.77.16.8801-8811.200310.1128/JVI.77.16.8801-8811.2003 ↗
17. 10.1074/jbc.M40075920010.1074/jbc.M400759200 ↗
18. 10.1016/j.drudis.2014.10.00310.1016/j.drudis.2014.10.003 ↗
19. 10.1093/infdis/jit12310.1093/infdis/jit123 ↗
20. 10.1038/ncomms406710.1038/ncomms4067 ↗
21. 10.1128/CMR.00056-0510.1128/CMR.00056-05 ↗
22. 10.1016/j.drudis.2013.05.01110.1016/j.drudis.2013.05.011 ↗
23. 10.1073/pnas.091456110710.1073/pnas.0914561107 ↗
24. 10.1021/nn304332s10.1021/nn304332s ↗
25. 10.1016/j.msec.2015.09.08010.1016/j.msec.2015.09.080 ↗
26. 10.1021/ja047029d10.1021/ja047029d ↗
27. 10.1016/S0169-409X(97)00131-210.1016/S0169-409X(97)00131-2 ↗
28. 10.1016/S0169-409X(97)00135-X10.1016/S0169-409X(97)00135-X ↗
29. 10.1016/j.taap.2008.12.02310.1016/j.taap.2008.12.023 ↗
30. 10.1158/1078-0432.CCR-10-097810.1158/1078-0432.CCR-10-0978 ↗
31. 10.1016/j.biomaterials.2009.11.07910.1016/j.biomaterials.2009.11.079 ↗
32. 10.1016/j.biomaterials.2007.12.03710.1016/j.biomaterials.2007.12.037 ↗